3487 completed, 1136 terminated, 946 recruiting, 755 unknown. 7544 Phase 2, 1933 Phase 1, 350 Phase 3.
Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sonrotoclax in Combination With Azacitidine for Previously Untreated Higher-risk Myelodysplastic Syndromes Each treatment cycle is 28-days. Azacitidine 75 mg/m² is administered subcutaneously or intravenously on Days 1-7 of each cycle. Sonrotoclax is orally administered once daily on Days 1-14 within each - MDS (Myelodysplastic Syndrome) | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 10 | 2028-09-01 | 2026-11-12 |
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| Prenatal Transplantation for Fetuses With Fanconi Anemia IUHSCT for FA-affected fetuses - Fanconi Anemia, Anemia, Hypoplastic, Congenital | Phase 1 / Phase 2 | Not yet recruiting | Agnieszka Czechowicz | 12 | 2028-01-01 | 2026-06-16 |
| A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 58 | 2027-12-01 | 2026-08-25 |
| Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma YKST02 - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 2 | Not yet recruiting | Excyte Biopharma Ltd | 64 | 2027-12-01 | 2026-11-06 |
| Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-11-01 | 2026-04-13 |
| Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 44 | 2027-08-04 | 2026-09-10 |
| Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy • Sivelestat intravenous infusion, NaCl intravenous infusion - Septic Shock, Coagulopathy | Phase 2 | Not yet recruiting | University Hospital, Strasbourg, France | 120 | 2027-08-01 | 2026-08-20 |
| Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®) - Aplastic Anaemia | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 59 | 2027-08-01 | 2026-10-21 |
| CAR-T Immunotherapy Targeting CD19- ALL 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-07-01 | 2026-11-02 |
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-11-04 |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-26 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy - Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | Zealand University Hospital | 150 | 2027-03-01 | 2026-09-25 |
| MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | University of Arkansas | 50 | 2027-03-01 | 2026-09-02 |
| A Study of Rusfertide in Adults With Polycythemia Vera in China Rusfertide - Polycythemia Vera | Phase 2 | Not yet recruiting | Takeda | 24 | 2027-03-01 | 2026-08-28 |
| Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine - Hematological Malignancies | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 70 | 2027-02-28 | 2026-08-20 |
| Teclistamab In Waldenstrom's Macroglobulinemia Teclistamab - Waldenstrom's Macroglobulinemia | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 24 | 2027-02-19 | 2026-09-01 |
| A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids. Ianalumab, Eltrombopag - Primary Immune Thrombocytopenia (ITP) | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 36 | 2027-02-08 | 2026-06-25 |
| Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 35 | 2027-01-30 | 2026-11-05 |
Showing 20 of 7544. Sign in to see all of them.
Multiple Myeloma (1584) · Leukemia, Myeloid, Acute (1555) · Leukemia (1047) · Myelodysplastic Syndromes (1007) · Leukemia, Lymphocytic, Chronic, B-Cell (920) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (899) · Lymphoma (582) · Lymphoma, Non-Hodgkin (499) · Recurrence (447) · Hematologic Neoplasms (433) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (404) · Lymphoma, Follicular (343) · Anemia (314) · Lymphoma, Mantle-Cell (311) · Lymphoma, Large B-Cell, Diffuse (308)
Hemic and Lymphatic Diseases (7542) · Neoplasms (5363) · Neoplasms by Histologic Type (5154) · Immune System Diseases (3989) · Immunoproliferative Disorders (3532) · Lymphoproliferative Disorders (3463) · Leukemia (2609) · Pathological Conditions, Signs and Symptoms (2482) · Pathologic Processes (2414) · Lymphatic Diseases (2257) · Hemorrhagic Disorders (2220) · Disease Attributes (2010) · Bone Marrow Diseases (1991) · Leukemia, Myeloid (1987)
Cyclophosphamide (775) · Dexamethasone (691) · Cytarabine (498) · Lenalidomide (386) · fludarabine (384) · fludarabine phosphate (363) · Rituximab (359) · Azacitidine (329) · Bortezomib (327) · venetoclax (318) · Melphalan (290) · Busulfan (282) · Filgrastim (278) · Methotrexate (272) · Calcium Dobesilate (227)
M.D. Anderson Cancer Center (436) · National Cancer Institute (NCI) (290) · Fred Hutchinson Cancer Center (171) · Memorial Sloan Kettering Cancer Center (136) · Novartis Pharmaceuticals (129) · Institute of Hematology & Blood Diseases Hospital, China (118) · Mayo Clinic (101) · National Heart, Lung, and Blood Institute (NHLBI) (89) · Masonic Cancer Center, University of Minnesota (77) · Dana-Farber Cancer Institute (68) · Peking University People's Hospital (64) · Amgen (56) · GlaxoSmithKline (56) · Celgene (55) · City of Hope Medical Center (54)
United States (4408) · China (846) · France (642) · Germany (595) · Italy (584) · Canada (513) · United Kingdom (498) · Spain (457) · Australia (309) · South Korea (249) · Netherlands (224) · Poland (209) · Belgium (204) · Japan (182) · Israel (171)
Jorge Cortes, MD (20) · Lei Zhang, MD (20)
PMID 36005278, PMID 41671463, PMID 32499241, PMID 34515338, PMID 35622074, PMID 36240296, PMID 33783815, PMID 33357481, PMID 34724566, PMID 23524640, PMID 34398557, PMID 37975597, PMID 23065508, PMID 28835440, PMID 29358183, PMID 29674506, PMID 30885996, PMID 30957581, PMID 33394722, PMID 36791280, PMID 39903535, PMID 42133908, PMID 23620574, PMID 23738544, PMID 24802773, PMID 27209293, PMID 29618479, PMID 29958797, PMID 30062662, PMID 32031570, PMID 32171076, PMID 33242441, PMID 34175041, PMID 35285981, PMID 35549810, PMID 36184192, PMID 37254256, PMID 37934000, PMID 19216617, PMID 19846889, PMID 21403127, PMID 22430088, PMID 25310303, PMID 25361995, PMID 26182309, PMID 26308596, PMID 26348869, PMID 27658437, PMID 28054442, PMID 29515037
2023 (79), P30CA015704 (73), P30CA015083 (59), 2018 (54), 2017 (52), U10CA180820 (46), 2014 (43), 2016 (43), 2015 (40), 2025 (39), 2019 (37), U10CA032102 (35), 2008 (34), U10CA031946 (34), 2009 (32)